<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01114048</url>
  </required_header>
  <id_info>
    <org_study_id>KMM-97</org_study_id>
    <nct_id>NCT01114048</nct_id>
  </id_info>
  <brief_title>Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)</brief_title>
  <acronym>KMM-97</acronym>
  <official_title>Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM) Who Are Eligible for Autologous Stem Cell Transplantation: Multicenter Phase 2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chonnam National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators will analyze the long-term outcomes of remission and&#xD;
      survival, and identify those with primary resistant disease as more likely to benefit from&#xD;
      CTD (thalidomide, cyclophosphamide, dexamethasone) and early intensification of Vel-CD&#xD;
      (bortezomib and CD) as induction chemotherapy followed by autologous stem cell&#xD;
      transplantation for the patients with newly diagnosed multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to assess the efficacy and toxicities of CTD and Vel-CD induction followed by&#xD;
      high-dose therapy with autologous stem cell transplantation as a first line treatment for the&#xD;
      patients with multiple myeloma.The investigators already investigated the thalidomide-based&#xD;
      chemotherapy in patients with newly diagnosed MM. The combined regimen consisted of&#xD;
      cyclophosphamide, thalidomide and dexamethasone (CTD) for induction treatment. CTD&#xD;
      chemotherapy resulted in a favorable response with 79.4% overall response rate including&#xD;
      42.6% complete response (CR) or very good partial complete response (VGPR), and tolerable&#xD;
      toxicity in MM patients. Moreover, CTD chemotherapy did not affect the yield of the stem cell&#xD;
      collection.The investigators also published that the clinical efficacy and safety of a&#xD;
      four-drug combination of bortezomib, cyclophosphamide, thalidomide, and dexamethasone was&#xD;
      assessed for patients with relapsed or refractory multiple myeloma Vel-CTD chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2010</start_date>
  <primary_completion_date type="Anticipated">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate for induction chemotherapy</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide, cyclophosphamide, dexamethasone, bortezomib</intervention_name>
    <description>Induction therapy with CTD regimen for 4 cycles Thalidomide 50-100 mg P.O. HS D 1~28 Cyclophosphamide 150 mg/m² P.O. D 1~4 Dexamethasone 20 mg/ m² IV or P.O. D 1~4, 15-18 Repeated every 28 days&#xD;
Intensification with Vel-CD regimen for 4 cycles (patients who fail to achieve more than PR after 2 cycles of CTD) Velcade 1.3 mg/m2 IV D1, 4, 8, 11 Cyclophosphamide 150 mg/m² P.O. D 1~4 Dexamethasone 20 mg/ m² IV or P.O. D1, 4, 8, 11 Repeated every 21 days&#xD;
Bactrim prophylaxis during dexamethasone administration Acyclovir prophylaxis during velcade administration Aspirin medication during thalidomide administration</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Newly diagnosed MM&#xD;
&#xD;
          2. Aged between 18 and 65 years old&#xD;
&#xD;
          3. With following measurable lesions (serum M-protein ≥ 1 g/dL or urine M-protein ≥ 400&#xD;
             mg/day, or free light chain ≥ 100 mg/L)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Smoldering or indolent myeloma&#xD;
&#xD;
          2. ECOG performance status &gt; 3 point&#xD;
&#xD;
          3. Known hypersensitivity to cyclophosphamide, thalidomide or dexamethasone&#xD;
&#xD;
          4. Peripheral neuropathy or neuropathic pain Grade 2 or higher as defined by NCI CTCAE&#xD;
             version 3&#xD;
&#xD;
          5. Uncontrolled or severe cardiovascular disease, including MI within 6 months of&#xD;
             enrolment, NYHA Class III or IV heart failure, uncontrolled angina, clinically&#xD;
             significant pericardial disease, or cardiac amyloidosis, cardiac ejection fraction&#xD;
             &lt;0.5 : Severe conduction disorder : Hypotension (sitting systolic BP ≤ 100 mmHg and/or&#xD;
             sitting diastolic BP ≤ 60 mmHg&#xD;
&#xD;
          6. Impaired hepatic function (AST or ALT ≥ x 3 upper normal, T-bilirubin ≥ x 2 upper&#xD;
             normal)&#xD;
&#xD;
          7. Creatinine clearance &lt; 20 ml/min&#xD;
&#xD;
          8. Corrected serum calcium ≥ 14 mg/dL&#xD;
&#xD;
          9. Sepsis or current active infection&#xD;
&#xD;
         10. Pregnancy or breast feeding&#xD;
&#xD;
         11. Uncontrolled Diabetes Mellitus&#xD;
&#xD;
         12. Previous history of Recurrent DVT or pulmonary embolism&#xD;
&#xD;
         13. Active ulcers detected by gastroscopy&#xD;
&#xD;
         14. Serious medical or psychiatric illness likely to interfere with participation in this&#xD;
             clinical study.&#xD;
&#xD;
         15. Receipt of extensive radiation therapy within 4 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Je-Jung Lee, M.D. and Ph.D.</last_name>
    <phone>82-61-3797638</phone>
    <email>drjejung@chonnam.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deok-Hwan Yang, M.D. and Ph.D.</last_name>
    <phone>82-61-3797636</phone>
    <email>drydh1685@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun-gun</city>
        <state>Jeollanam-do</state>
        <zip>519-809</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Je-Jung Lee, M.D. and Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>April 28, 2010</study_first_submitted>
  <study_first_submitted_qc>April 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2010</study_first_posted>
  <last_update_submitted>September 21, 2011</last_update_submitted>
  <last_update_submitted_qc>September 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Je-Jung Lee, associate professor</name_title>
    <organization>Chonnam National University Hwasun Hospital</organization>
  </responsible_party>
  <keyword>age under 65</keyword>
  <keyword>Previous untreated</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

